Literature DB >> 17355100

Investigating genetic discrimination in the Australian life insurance sector: the use of genetic test results in underwriting, 1999-2003.

Margaret Otlowski1, Kristine Barlow-Stewart, Sandra Taylor, Mark Stranger, Susan Treloar.   

Abstract

A major component of the Genetic Discrimination Project (GDP), an Australia-wide study to examine the advantages and disadvantages for individuals of having genetic information and cases of alleged genetic discrimination, is the analysis of insurers' use of genetic test results. The peak life insurance body, IFSA, had collected data through the Australian Institute of Actuaries (AIA) for the period June 1999-May 2003 from life insurance companies in Australia regarding their use of genetic test results in insurance underwriting. The GDP negotiated with IFSA and the AIA for access to this data for independent analysis. Applications from 288 individuals who had disclosed a genetic test result included products for cover for death, trauma/crisis, income protection/disability and total and permanent disablement. A total of 81% (234/288) contained usable data for analysis. These cases involved the genetic conditions haemochromatosis (71%), Huntington disease (12%) and breast/ovarian cancer (6%). In 49% of cases, the genetic test result was described as the only influencing factor and of these, 32% involved a "positive" genetic test result. Whilst underwriting in most cases appeared to be reasonable, the article highlights several cases involving disclosure of a positive predictive test result for breast/ovarian cancer that required further investigation.

Entities:  

Mesh:

Year:  2007        PMID: 17355100

Source DB:  PubMed          Journal:  J Law Med        ISSN: 1320-159X


  8 in total

1.  Comparative perspectives: regulating insurer use of genetic information.

Authors:  Anya E R Prince
Journal:  Eur J Hum Genet       Date:  2018-11-06       Impact factor: 4.246

2.  You never call, you never write: why return of 'omic' results to research participants is both a good idea and a moral imperative.

Authors:  Misha Angrist
Journal:  Per Med       Date:  2011-11       Impact factor: 2.512

3.  Study protocol: the Australian genetics and life insurance moratorium-monitoring the effectiveness and response (A-GLIMMER) project.

Authors:  Louise Keogh; Paul Lacaze; Jane Tiller; Aideen McInerney-Leo; Andrea Belcher; Tiffany Boughtwood; Penny Gleeson; Martin Delatycki; Kristine Barlow-Stewart; Ingrid Winship; Margaret Otlowski
Journal:  BMC Med Ethics       Date:  2021-05-21       Impact factor: 2.652

4.  Should Australia Ban the Use of Genetic Test Results in Life Insurance?

Authors:  Jane Tiller; Margaret Otlowski; Paul Lacaze
Journal:  Front Public Health       Date:  2017-12-13

5.  Genetic discrimination by Australian insurance companies: a survey of consumer experiences.

Authors:  Jane Tiller; Susan Morris; Toni Rice; Krystal Barter; Moeen Riaz; Louise Keogh; Martin B Delatycki; Margaret Otlowski; Paul Lacaze
Journal:  Eur J Hum Genet       Date:  2019-07-08       Impact factor: 4.246

Review 6.  Massively Parallel Sequencing for Rare Genetic Disorders: Potential and Pitfalls.

Authors:  Aideen M McInerney-Leo; Emma L Duncan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-19       Impact factor: 5.555

Review 7.  Genetic discrimination and life insurance: a systematic review of the evidence.

Authors:  Yann Joly; Ida Ngueng Feze; Jacques Simard
Journal:  BMC Med       Date:  2013-01-31       Impact factor: 8.775

8.  How are genetic test results being used by Australian life insurers?

Authors:  K Barlow-Stewart; M Liepins; A Doble; M Otlowski
Journal:  Eur J Hum Genet       Date:  2018-06-11       Impact factor: 4.246

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.